Zepbound Pricing in 2026: List Price, Copay Card, Vial Pricing, and the Cash-Pay Alternative

Key Takeaways

• The list price for Zepbound auto-injector pens is roughly $1,086 per month before any discounts in 2026.
• Eli Lilly's self-pay vial program prices Zepbound at $349 for the 2.5 mg dose and $499 for 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose vials, no insurance required.
• Patients with commercial insurance that covers Zepbound can pay as little as $25 per month for up to 13 fills with the manufacturer savings card.
• Medicare and Medicaid patients are excluded from the savings card and from the cash-pay vial program in most cases.
• Compounded tirzepatide through a licensed telehealth platform typically prices between $179 and $399 per month and skips insurance entirely.

Direct answer (40-60 words)

Zepbound pricing in 2026 ranges from $25 per month with a manufacturer savings card and commercial insurance, to $349 to $499 per month for self-pay vials through Lilly's direct program, to a list price of about $1,086 per month at retail pharmacies without coverage. Compounded tirzepatide alternatives run $179 to $399 monthly.

Table of contents

1. The 30-second answer
2. Zepbound list price by dose
3. Zepbound with commercial insurance
4. The Zepbound savings card
5. Zepbound self-pay vial program
6. Medicare and Medicaid coverage
7. Zepbound vs Wegovy pricing
8. Five factors that move your real cost
9. Compounded tirzepatide pricing
10. How to confirm your real Zepbound cost
11. FAQ
12. Sources
13. Footer disclaimers

Zepbound list price by dose

The wholesale acquisition cost (WAC) for Zepbound was set by Eli Lilly in late 2023 and has held roughly stable through 2026. Retail pharmacies add their dispensing margin on top of that, which is why the price you see at the counter is a little higher than the published list price.

Dose	Monthly list price (approx.)	4-week supply
2.5 mg auto-injector pen	$1,059 to $1,086	4 pens
5 mg auto-injector pen	$1,059 to $1,086	4 pens
7.5 mg auto-injector pen	$1,059 to $1,086	4 pens
10 mg auto-injector pen	$1,059 to $1,086	4 pens
12.5 mg auto-injector pen	$1,059 to $1,086	4 pens
15 mg auto-injector pen	$1,059 to $1,086	4 pens

Notice the list price is roughly the same across all six doses. Lilly chose flat pricing so titration up to a higher dose doesn't financially punish patients (Eli Lilly press release, 2023). The retail "real" price you'll see at your pharmacy can run slightly higher because of pharmacy margin, dispensing fees, and your specific zip code.

For comparison, that same monthly cost works out to about $36 per day, or $13,000 per year if you stay on the medication continuously without any insurance or assistance.

Zepbound with commercial insurance

Whether your commercial insurance plan covers Zepbound depends on three things: whether your employer or marketplace plan includes anti-obesity medication coverage at all, what tier Zepbound sits on in that plan's formulary, and whether prior authorization is required.

A 2024 KFF analysis found that about 29% of large employers covered GLP-1 medications for weight loss, up from roughly 16% in 2023 (KFF Employer Health Benefits Survey, 2024). The trend is upward, but a majority of commercial plans still exclude weight-loss coverage even when they cover the same molecules for diabetes.

If your plan does cover Zepbound, your costs typically fall into one of these buckets:

• Tier 2 preferred brand: $40 to $80 monthly copay after deductible
• Tier 3 non-preferred brand: $100 to $250 monthly copay after deductible
• Tier 4 specialty tier: 20% to 40% coinsurance after deductible
• Excluded entirely: full cash price (about $1,086) or use the savings card alternatives below

Most plans require prior authorization with a documented BMI of 30 (or 27 with a comorbidity such as hypertension, dyslipidemia, or sleep apnea). The PA process takes 3 to 14 days. A 2024 GoodRx survey found that 41% of Zepbound prior authorization requests were denied on first submission and required appeal.

The Zepbound savings card

Eli Lilly's Zepbound Savings Card is the manufacturer's commercial-copay assistance program. It's the most accessible path to the lowest possible price for patients with commercial insurance.

With covered insurance: as little as $25 per month for up to 13 fills, with the card paying up to a $469 maximum benefit per fill.

Without covered insurance (commercial plan that doesn't cover Zepbound): as little as $650 per month, again for up to 13 fills.

Eligibility:

• Commercial insurance (not Medicare, Medicaid, TRICARE, or VA)
• U.S. residency
• Prescription for chronic weight management consistent with FDA labeling

Exclusions:

• Anyone enrolled in any government-sponsored prescription program
• Anyone outside the United States
• Anyone using Zepbound off-label outside the FDA's approved indications

The card resets after 13 fills, but Lilly has historically allowed re-enrollment. Read the current card terms before assuming the second 13-fill cycle starts automatically. The savings card stacks with insurance copay accumulators differently depending on your plan, so it's worth asking your benefits administrator how the card affects your deductible math.

Zepbound self-pay vial program

In August 2024, Eli Lilly launched a direct cash-pay program selling single-dose Zepbound vials at a discount to the auto-injector pen list price. The program runs through LillyDirect, a Lilly-operated direct-to-patient pharmacy.

2026 pricing for the self-pay vial program:

Dose	Monthly self-pay vial price	Savings vs list price
2.5 mg vial	$349	About 68% off
5 mg vial	$499	About 54% off
7.5 mg vial	$499	About 54% off
10 mg vial	$499	About 54% off
12.5 mg vial	$499	About 54% off
15 mg vial	$499	About 54% off

The vials ship in a four-pack (one month's supply) and require the patient to draw the dose with a U-100 insulin syringe. They're not pre-filled like the auto-injector pen.

Eligibility for vial pricing:

• Valid Zepbound prescription
• Not using insurance to pay for Zepbound (this is a self-pay alternative, not a copay reducer)
• U.S. resident
• Available through LillyDirect only, not through retail pharmacies

The vial program was created partly as a supply-shortage response and partly as a self-pay accessibility play. Vials can be cheaper to manufacture than pens, and Lilly chose to pass that savings to patients who would otherwise be priced out (Eli Lilly press release, 2024).

Medicare and Medicaid coverage

Medicare's coverage of Zepbound is limited and dose-specific.

Medicare Part D: Medicare doesn't cover anti-obesity medications under federal law (Social Security Act, Section 1860D-2(e)(2)(A)), with one growing exception. In late 2024, CMS issued guidance that GLP-1 medications prescribed for cardiovascular risk reduction in patients with established cardiovascular disease may be covered if the FDA approves the indication. Wegovy received that label expansion first, in March 2024 (FDA approval letter, 2024). Zepbound's cardiovascular outcomes data is still maturing as of 2026, and Medicare coverage for the cardiovascular indication is plan-dependent.

Medicaid: state-by-state. As of early 2026, fewer than 15 states cover Zepbound for weight loss in their Medicaid programs. Coverage typically requires BMI documentation, prior authorization, and adherence to step therapy.

Tricare and VA: Tricare covers Zepbound with prior authorization for FDA-approved indications. The VA's formulary status varies by region.

If you're on Medicare or Medicaid and Zepbound isn't covered, the Lilly self-pay vial program is generally available regardless of your insurance status (read the current LillyDirect terms before enrolling). The Zepbound Savings Card, however, isn't.

Zepbound vs Wegovy pricing

Pricing element	Zepbound	Wegovy
List price (monthly)	About $1,086	About $1,349
Manufacturer savings card (with covered insurance)	As low as $25	As low as $0
Manufacturer savings card (without covered insurance)	As low as $650	As low as $499
Self-pay direct program	$349 to $499 (vials)	Not currently available
Active ingredient	Tirzepatide	Semaglutide
Mechanism	Dual GIP and GLP-1 agonist	GLP-1 agonist only

Zepbound is the only GLP-1 weight-loss medication on the U.S. market with both an auto-injector pen and a discounted cash-pay vial program. That makes it the more flexible option for patients who don't have insurance coverage and want to avoid compounded alternatives.

In the SURMOUNT-1 trial, average weight loss at 72 weeks for the 15 mg tirzepatide group was 22.5%, compared to about 14.9% for semaglutide 2.4 mg in STEP 1 at 68 weeks (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). Head-to-head data became available with the SURMOUNT-5 trial in 2025, which showed tirzepatide produced about 47% greater weight loss than semaglutide over 72 weeks (Aronne et al., NEJM 2025).

Five factors that move your real cost

Factor 1: Whether your plan covers GLP-1s for weight loss at all. This is the single biggest variable. A "no" here forces you into the savings card without coverage track ($650/month) or the self-pay vial program ($349 to $499/month).

Factor 2: Your formulary tier. If your plan does cover Zepbound, the tier dictates whether you pay $50 or $400 per fill before the savings card.

Factor 3: Deductible status. Most commercial plans require you to meet your annual deductible before copay tiers kick in. If your deductible is $3,500 and it's January, your first few Zepbound fills may be billed at the full negotiated rate.

Factor 4: Prior authorization approval. A denied PA forces you into cash pricing or savings card pricing without coverage. Appeals can take weeks.

Factor 5: Whether you accept the auto-injector pen vs the vial. The vial is roughly half the cost. The trade-off is patient effort: drawing your own dose with a syringe rather than pressing a button on a pre-filled pen.

Compounded tirzepatide pricing

For patients who are priced out of brand-name Zepbound and don't qualify for assistance, compounded tirzepatide is the most common alternative. A 503A or 503B compounding pharmacy prepares the medication in response to an individual prescription written by a licensed provider.

Typical compounded tirzepatide pricing (2026):

• FormBlends: $179 to $399 per month, dose-titrated
• Other licensed telehealth platforms: $199 to $499 per month
• Local 503A pharmacies (cash pay): $200 to $400 per month

Trade-offs vs brand-name Zepbound:

• Compounded tirzepatide is not FDA-approved
• It's drawn from a vial with a U-100 insulin syringe, not delivered by a pre-filled pen
• It's not interchangeable with Zepbound and shouldn't be presented as the same medication
• It typically isn't covered by insurance (it's a cash-pay model)
• It bypasses the manufacturer-set list price and goes through compounding pharmacies that source the active ingredient from FDA-registered facilities

When compounded tirzepatide makes sense:

• Your insurance doesn't cover Zepbound
• You don't qualify for the manufacturer savings card or vial program
• The Lilly self-pay price is still out of reach
• You want predictable monthly cash pricing without insurance paperwork

A licensed clinician walks through both options with each patient. Compounded medications have a place, but they're not equivalents to FDA-approved drugs and shouldn't be sold as such. (See our comparison of compounded vs brand-name semaglutide for a deeper read on the regulatory and clinical differences.)

How to confirm your real Zepbound cost

Step 1: Check your insurance formulary. Log into your insurance member portal and search "tirzepatide" or "Zepbound." Note the tier and any prior authorization requirements.

Step 2: Run a test claim at your pharmacy. Most retail pharmacies will run a no-charge test claim against your insurance to return your exact copay. Call the pharmacy or use the chain's app.

Step 3: Check the Zepbound Savings Card terms. Visit the official Lilly Zepbound site to confirm current eligibility and benefit amounts.

Step 4: Compare to the LillyDirect vial price. If your insured copay is over $349 per month, the vial program may be cheaper.

Step 5: Get a compounded quote as a backup. A licensed telehealth provider can quote compounded tirzepatide pricing in 5 minutes.

Step 6: Document your decision and stay consistent. Switching between brand and compounded formulations mid-titration introduces avoidable variability. Pick a track and stay on it for at least 12 weeks before reassessing.

FAQ

How much does Zepbound cost without insurance?

The retail list price is about $1,086 per month. Eli Lilly's LillyDirect self-pay vial program offers Zepbound for $349 (2.5 mg) or $499 (5 mg through 15 mg) per month with no insurance required.

How much does Zepbound cost with insurance?

Patients with commercial insurance that covers Zepbound typically pay $25 to $250 per month with the manufacturer savings card. The exact amount depends on your formulary tier, deductible, and savings card eligibility.

What is the cheapest way to get Zepbound?

For most patients with commercial insurance, the Zepbound Savings Card delivers the lowest brand-name price (as low as $25 per month). Without coverage, the LillyDirect $349 vial pricing is the cheapest official option. Compounded tirzepatide can be even lower at $179 to $399 monthly, though it's not the same product.

Does Medicare cover Zepbound?

Medicare doesn't generally cover Zepbound for weight loss because federal law excludes anti-obesity medications from Part D. Coverage may be available for cardiovascular indications once Zepbound has FDA approval for that use and your specific Part D plan adds the indication to its formulary.

Why is Zepbound so expensive?

Zepbound is a brand-name biologic with a complex manufacturing process, an active patent, and significant clinical trial costs. The list price reflects what U.S. pharmaceutical pricing models charge for novel injectable therapies. Generics and biosimilars aren't expected before the late 2030s.

Is Zepbound cheaper than Wegovy?

At list price, Zepbound is about $263 less per month than Wegovy. With manufacturer savings cards, both can come down to similar copays for patients with commercial coverage. Without coverage, Zepbound has the additional advantage of the LillyDirect vial program.

What is the Zepbound savings card maximum benefit?

The savings card pays up to a $469 benefit per fill, applied for up to 13 fills. Patients on covered insurance pay as little as $25 per month. Patients on commercial insurance that doesn't cover Zepbound pay as low as $650 per month with the card applied.

Does Costco or Walmart sell Zepbound cheaper?

Cash prices at major retail chains (Costco, Walmart, CVS, Sam's Club) are typically within $50 of each other. Insurance-driven copays are nearly identical across chains because the same negotiated rate applies. The LillyDirect vial program is cheaper than any retail pharmacy cash price.

Can I use GoodRx with Zepbound?

GoodRx coupons can apply to brand-name Zepbound at participating pharmacies, typically reducing the cash price by $50 to $200. They don't combine with the manufacturer savings card. Compare both before filling.

Is compounded tirzepatide safe?

Compounded tirzepatide prepared by a state-licensed 503A or 503B pharmacy under a valid prescription has an established safety record, but compounded medications haven't gone through the FDA's approval process and aren't interchangeable with Zepbound. Discuss the trade-offs with a licensed clinician.

Will Zepbound get cheaper in 2026 or 2027?

Possibly. Lilly has expanded the LillyDirect vial program twice since launch, and competitive pressure from oral GLP-1s and biosimilars may push prices down further. Major price drops typically follow patent expirations, which for tirzepatide aren't expected until the mid-to-late 2030s.

What if I lose coverage mid-titration?

Talk to your provider before stopping. Your options include the LillyDirect vial program, the savings card without coverage benefit, or transitioning to compounded tirzepatide. Stopping abruptly can cause weight regain over the following months (Wilding et al., Diabetes Obes Metab 2022).

Related guides

• How Much Does Rybelsus Cost in 2026? The Real Price Breakdown and 5 Ways to Pay Less Than List Price
• Zepbound Pricing: Complete Cost Breakdown, Insurance Coverage, and How to Pay $300 Instead of $1,060
• GLP-1 Drugs Oral List: Every FDA-Approved Pill, Compounded Alternative, and When Oral Formulations Actually Work Better Than Injections
• Does Cigna Cover Zepbound? The 2026 Coverage Rules, Copay Ranges, and Prior Authorization Requirements
• How to Get Zepbound for $25: Every Legitimate Path to the Savings Card, Patient Assistance, and Compounded Alternatives
• What Tier Is Zepbound on Your Insurance Formulary, and Why It Determines What You Actually Pay
• Tool: cost calculator

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
3. Aronne LJ, et al. Tirzepatide vs semaglutide once weekly in adults with obesity (SURMOUNT-5). N Engl J Med. 2025.
4. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564.
5. Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. Indianapolis, IN; revised 2024.
6. Eli Lilly and Company. Zepbound launches single-dose vial self-pay program through LillyDirect. Press release, August 2024.
7. KFF. Employer Health Benefits Survey 2024. Kaiser Family Foundation; 2024.
8. GoodRx Research. Prior authorization survey: GLP-1 medications. GoodRx; 2024.
9. Centers for Medicare and Medicaid Services. Medicare Part D coverage of anti-obesity medications: guidance update. CMS; 2024.
10. U.S. Food and Drug Administration. Wegovy (semaglutide) approval letter for cardiovascular indication. FDA; March 2024.
11. Social Security Act, Section 1860D-2(e)(2)(A): exclusion of anti-obesity drugs from Medicare Part D.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.